- GSK/BioNTech/Pfizer: Additional mRNA litigation April 26, 2024
- Cidara Therapeutics: Cidara Therapeutics reacquires global rights to CD388 from Johnson & Johnson, announces financing of 240 million USD, will proceed with CD388 phase 2b study in autumn 2024 April 24, 2024
- Cidara Therapeutics: Divestiture of rezafungin to focus on Cloudbreak DFC pipeline, including CD388 April 24, 2024
- CureVac/GSK: Start of combined phase 1/2 study for avian influenza (H5N1) mRNA vaccine April 24, 2024
- CureVac/GSK: Promising interim data from mRNA seasonal influenza vaccine phase 2 study April 4, 2024
- SAB Biotherapeutics: Partnership with Naval Medical Research Center for SAB-176 study March 25, 2024
- BioNTech/CureVac: German court voids CureVac patent after BioNTech challenge, stock drops 41% December 19, 2023
- BioNTech/Moderna: EPO revokes Moderna patent in vaccine dispute with BioNTech November 21, 2023
- GSK: GSK sells Haleon shares to sharpen its focus on vaccines and infectious diseases October 7, 2023
- BioNTech/Pfizer: Pfizer and BioNTech resolve mRNA patent lawsuit filed by Promosome October 7, 2023
- Moderna: mRNA-1010 Seasonal Influenza Vaccine phase 3 study successfully completed September 13, 2023
- CureVac/GSK: mRNA seasonal influenza vaccine development advances to phase 2 study September 12, 2023
- Cidara Therapeutics/Johnson & Johnson: CD388 cooperation will continue, stock +26% September 6, 2023
- Vir Biotechnology: VIR-2981 appears on pipeline page, indicating GSK collaboration August 6, 2023
- Moderna: mRNA-1010 phase 3 study data coming soon? July 23, 2023
- Cidara Therapeutics/Johnson & Johnson: CD388 study continuation uncertain July 21, 2023
- Vir Biotechnology: VIR-2482 phase 2 study failed, stock drops 44% July 20, 2023
- BioCryst Pharmaceuticals: BofA upgraded BioCryst (BCRX) to Buy from Neutral with a $10 price target July 13, 2023
- Cidara Therapeutics: CD388 phase 2 study data coming soon? July 13, 2023
- Vir Biotechnology: VIR-2482 phase 2 study data coming soon? July 13, 2023
News